— Tandem Diabetes (NASDAQ: TNDM) reported earnings of $0.04 per share in the fourth quarter of 2019, vs $0.05 per share loss expected
— Q4 Sales grew 42% to $108.4 million, vs. $109.2 million expected
— Worldwide pump shipments increased 21% to 19,602 pumps in Q4
— For FY20, sales are estimated to be in the range of $450 million to $465 million, up 24% to 28%. Adjusted EBITDA is estimated to be 12% to 14%
— TNDM fell 3.8% immediately following the announcement.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
